trial · primary record
Pembrolizumab
Hodgkin's Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 66 |
| Primary completion | 2025-10-13 |
| Primary endpoint | Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator |
| Registry ID | NCT04875195 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:38.030Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04875195
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.